secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001104659-23-128806
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports FY2023 net loss of $59M, reiterates ONS-5010 path with NORSE EIGHT trial start in Q1 2024
--------------------------------------------------------------------------------

- Net loss of $59.0M ($0.24 per share) for FY2023, vs. $66.1M ($0.31 per share) prior year.
- Cash and equivalents $23.4M as of Sept 30, 2023; extended convertible note maturity to April 1, 2024.
- FDA response on NORSE EIGHT SPA expected early Feb 2024; trial start targeted Q1 2024.
- MAA decision in EU for ONS-5010 (LYTENAVA) anticipated first half 2024; BLA resubmission expected by end of 2024.
- Exploring expanded relationship with Cencora for international launch; Syntone partnership in China continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923128806/0001104659-23-128806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923128806/tm2333600d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-128806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer